We investigated the effect of Ropeginterferon alfa-2b (Ropeg) versus phlebotomy-only (Phl-O) on the neutrophil-to-lymphocyte ratio (NLR) in 126 patients randomized in the low-polycythaemia vera (PV) phase II trial. Patients with a baseline NLR >= 3.5 vs. <3.5 had a longer history of PV, were more likely to have splenomegaly, higher JAK2V617F variant allele frequency (VAF) (56% vs. 20% p = 0.001) and more proliferative disease. Ropeg was superior to Phl-O in reducing NLR (p = 0.008), and the reduction was strongly influenced by the reduction in neutrophils and less by a change in lymphocytes (-59% and -14% respectively). This effect was associated with the achievement of the low-PV primary end-point (p = 0.021), symptom reduction and reduction in JAK2 VAF. Interestingly, the reduction in JAK2 VAF from baseline was linearly associated with the reduction in NLR. Patients who failed Phl-O at 12 months had characteristics that distinguished them from responders, including very high NLR and resistance to cross-over to 100 mu g Ropeg every 2 weeks suggesting higher escalated doses of Ropeg. In conclusion, the study provides evidence that NLR can serve as a valuable biomarker to assess and guide treatment with Ropeg in the early stage of low-risk PV patients.

Neutrophil/lymphocyte ratio identifies low-risk polycythaemia vera patients for early Ropeginterferon alfa-2b therapy / Barbui, T.; Carobbio, A.; Guglielmelli, P.; Ghirardi, A.; Fenili, F.; Loscocco, G. G.; De , ; Stefano, V.; Ramundo, F.; Finazzi, M. C.; Rambaldi, A.; Vannucchi, A. M.. - In: BRITISH JOURNAL OF HAEMATOLOGY. - ISSN 0007-1048. - 205:6(2024), pp. 2287-2294. [10.1111/bjh.19813]

Neutrophil/lymphocyte ratio identifies low-risk polycythaemia vera patients for early Ropeginterferon alfa-2b therapy

Carobbio A.;
2024

Abstract

We investigated the effect of Ropeginterferon alfa-2b (Ropeg) versus phlebotomy-only (Phl-O) on the neutrophil-to-lymphocyte ratio (NLR) in 126 patients randomized in the low-polycythaemia vera (PV) phase II trial. Patients with a baseline NLR >= 3.5 vs. <3.5 had a longer history of PV, were more likely to have splenomegaly, higher JAK2V617F variant allele frequency (VAF) (56% vs. 20% p = 0.001) and more proliferative disease. Ropeg was superior to Phl-O in reducing NLR (p = 0.008), and the reduction was strongly influenced by the reduction in neutrophils and less by a change in lymphocytes (-59% and -14% respectively). This effect was associated with the achievement of the low-PV primary end-point (p = 0.021), symptom reduction and reduction in JAK2 VAF. Interestingly, the reduction in JAK2 VAF from baseline was linearly associated with the reduction in NLR. Patients who failed Phl-O at 12 months had characteristics that distinguished them from responders, including very high NLR and resistance to cross-over to 100 mu g Ropeg every 2 weeks suggesting higher escalated doses of Ropeg. In conclusion, the study provides evidence that NLR can serve as a valuable biomarker to assess and guide treatment with Ropeg in the early stage of low-risk PV patients.
2024
205
6
2287
2294
Neutrophil/lymphocyte ratio identifies low-risk polycythaemia vera patients for early Ropeginterferon alfa-2b therapy / Barbui, T.; Carobbio, A.; Guglielmelli, P.; Ghirardi, A.; Fenili, F.; Loscocco, G. G.; De&nbsp;, ; Stefano, V.; Ramundo, F.; Finazzi, M. C.; Rambaldi, A.; Vannucchi, A. M.. - In: BRITISH JOURNAL OF HAEMATOLOGY. - ISSN 0007-1048. - 205:6(2024), pp. 2287-2294. [10.1111/bjh.19813]
Barbui, T.; Carobbio, A.; Guglielmelli, P.; Ghirardi, A.; Fenili, F.; Loscocco, G. G.; De , ; Stefano, V.; Ramundo, F.; Finazzi, M. C.; Rambaldi,...espandi
File in questo prodotto:
File Dimensione Formato  
Br J Haematol - 2024 - Barbui - Neutrophil lymphocyte ratio identifies low‐risk polycythaemia vera patients for early.pdf

Accesso riservato

Tipologia: VOR - Versione pubblicata dall'editore
Dimensione 2.41 MB
Formato Adobe PDF
2.41 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1365430
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 2
social impact